Helaina’s Post

We’re thrilled to announce that Helaina has raised a $45 Series B to accelerate the commercialization of bioactive proteins starting with effera™ human lactoferrin. This infusion of new capital marks our next phase of growth and is the result of years of our dedicated team’s work to drive innovation and scientific rigor within nutrition. At this pivotal moment in our journey, we’re proud to partner with Avidity Partners, an investment firm with an outstanding reputation for supporting best-in-class biotech companies rooted in clinically-backed science. To learn more about what we’re building and our commercial launch, check out AgFunder’s piece. https://lnkd.in/erAtXXya

Helaina raises $45m series B round to support market entry of human lactoferrin

Helaina raises $45m series B round to support market entry of human lactoferrin

https://agfundernews.com

Congratulations on this remarkable milestone!

Like
Reply
Bruce Li

CEO at TJX Bioengineering | Leading Bioreactor Innovations

2mo

Keep growing 🎆 🎆 🎆

Like
Reply
Dina Radenkovic Turner

Co-founder & CEO at Gameto - Redefining Female Reproductive Health

2mo

Congratulations Laura Katz & Helaina team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics